Key host-pathogen interactions for designing novel interventions against Helicobacter pylori

Trends in Microbiology

Volumn 21, Issue 5, 2013, Pages 253-259

  Every, Alison L ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Adjuvant; Antioxidant; Helicobacter pylori; Mucin; Stomach pH; Vaccine

Indexed keywords

AGGLUTININ; ALKYLHYDROPEROXIDE REDUCTASE; ALUMINUM POTASSIUM SULFATE; AMOXICILLIN; ANTIBIOTIC AGENT; CAGA PROTEIN; CATALASE; CHOLERA TOXIN; CLARITHROMYCIN; HELICOBACTER PYLORI VACCINE; HOST FACTOR; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; ISCOMATRIX; MUCIN 1; OMEPRAZOLE; PROTON PUMP INHIBITOR; SUPEROXIDE DISMUTASE; THIOLPEROXIDASE; UNCLASSIFIED DRUG; VACUOLATING TOXIN; VIRULENCE FACTOR;

ADJUVANT THERAPY; ANTIBIOTIC RESISTANCE; ANTIBODY RESPONSE; BACTERIAL COLONIZATION; BACTERIAL LOAD; CHRONIC INFLAMMATION; HELICOBACTER FELIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE EVASION; MUCOSAL IMMUNITY; NONHUMAN; PATHOGENICITY ISLAND; PEYER PATCH; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; STOMACH PH; TYPE IV SECRETION SYSTEM; VARIABLE NUMBER OF TANDEM REPEAT;

ANIMALS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HOST-PATHOGEN INTERACTIONS; HUMANS;

BACTERIA (MICROORGANISMS); HELICOBACTER PYLORI;

EID: 84877116381     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2013.02.007     Document Type: Review

References (77)

1. Covacci A., et al. Helicobacter pylori virulence and genetic geography. Science 1999, 284:1328-1333.
2. International Agency for Research on Cancer, (1994) Schistosomes, Liver Flukes and Helicobacter pylori (Report of the IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, Lyon, 7-14 June 1994), IARC Monographs on the Evaluation of Carcinogenic Risks to Humans (Vol. 61), World Health Organization.
3. World Health Organization The Global Burden of Disease: 2004 Update 2008, http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf.
4. Censini S., et al. cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:14648-14653.
5. Parsonnet J., et al. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 1997, 40:297-301.
6. Covacci A., Rappuoli R. Tyrosine-phosphorylated bacterial proteins: Trojan horses for the host cell. J. Exp. Med. 2000, 191:587-592.
7. Viala J., et al. Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nat. Immunol. 2004, 5:1166-1174.
8. Yamaoka Y. Mechanisms of disease: Helicobacter pylori virulence factors. Nat. Rev. Gastroenterol. Hepatol. 2010, 7:629-641.
9. Olbermann P., et al. A global overview of the genetic and functional diversity in the Helicobacter pylori cag pathogenicity island. PLoS Genet. 2010, 6:e1001069.
10. Kwok T., et al. Helicobacter exploits integrin for type IV secretion and kinase activation. Nature 2007, 449:862-866.
11. Gorrell R.J., et al. A novel NOD1- and CagA-independent pathway of interleukin-8 induction mediated by the Helicobacter pylori type IV secretion system. Cell. Microbiol. 2013, 15:554-570.
12. Peek R.M., et al. Role of innate immunity in Helicobacter pylori-induced gastric malignancy. Physiol. Rev. 2010, 90:831-858.
13. Backert S., et al. Virulence factors of Helicobacter pylori. Helicobacter pylori In The 21st Century 2010, 212-247. CABI. P. Sutton, H.M. Mitchell (Eds.).
14. Sutton P., et al. Host genetic factors in susceptibility and resistance to Helicobacter pylori pathogenesis. Helicobacter pylori In The 21st Century 2010, 116-141. CABI. P. Sutton, H.M. Mitchell (Eds.).
15. Amieva M.R., El-Omar E.M. Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology 2008, 134:306-323.
16. Linden S.K., et al. Mucins in the mucosal barrier to infection. Mucosal Immunol. 2008, 1:183-197.
17. Hilkens J., et al. Cell membrane-associated mucins and their adhesion-modulating property. Trends Biochem. Sci. 1992, 17:359-363.
18. Leong C.F., et al. Epithelial membrane antigen (EMA) or MUC1 expression in monocytes and monoblasts. Pathology 2003, 35:422-427.
19. Agrawal B., et al. Expression of MUC1 mucin on activated human T cells: implications for a role of MUC1 in normal immune regulation. Cancer Res. 1998, 58:4079-4081.
20. Brugger W., et al. Expression of MUC-1 epitopes on normal bone marrow: implications for the detection of micrometastatic tumor cells. J. Clin. Oncol. 1999, 17:1535-1544.
21. Wykes M., et al. MUC1 epithelial mucin (CD227) is expressed by activated dendritic cells. J. Leukoc. Biol. 2002, 72:692-701.
22. Litvinov S.V., Hilkens J. The epithelial sialomucin, episialin, is sialylated during recycling. J. Biol. Chem. 1993, 268:21364-21371.
23. Carson D.D. The cytoplasmic tail of MUC1: a very busy place. Sci. Signal. 2008, 1:pe35.
24. Quin R.J., McGuckin M.A. Phosphorylation of the cytoplasmic domain of the MUC1 mucin correlates with changes in cell-cell adhesion. Int. J. Cancer 2000, 87:499-506.
25. Kyo Y., et al. Antiinflammatory role of MUC1 mucin during infection with nontypeable Haemophilus influenzae. Am. J. Respir. Cell Mol. Biol. 2012, 46:149-156.
26. Li Y., et al. Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin. Mol. Cell. Biol. 1998, 18:7216-7224.
27. Li Y., et al. DF3/MUC1 signaling in multiple myeloma cells is regulated by interleukin-7. Cancer Biol. Ther. 2003, 2:187-193.
28. Li Y., et al. The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin. J. Biol. Chem. 2001, 276:35239-35242.
29. Li Y., et al. The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 beta and beta-catenin. J. Biol. Chem. 2001, 276:6061-6064.
30. Ren J., et al. Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling. J. Biol. Chem. 2002, 277:17616-17622.
31. Vinall L.E., et al. Altered expression and allelic association of the hypervariable membrane mucin MUC1 in Helicobacter pylori gastritis. Gastroenterology 2002, 123:41-49.
32. Carvalho F., et al. MUC1 gene polymorphism and gastric cancer - an epidemiological study. Glycoconj. J. 1997, 14:107-111.
33. Saeki N., et al. A functional single nucleotide polymorphism in mucin 1, at chromosome 1q22, determines susceptibility to diffuse-type gastric cancer. Gastroenterology 2011, 140:892-902.
34. McGuckin M.A., et al. Muc1 mucin limits both Helicobacter pylori colonization of the murine gastric mucosa and associated gastritis. Gastroenterology 2007, 133:1210-1218.
35. Every A.L., et al. Muc1 limits Helicobacter felis binding to gastric epithelial cells but does not limit colonization and gastric pathology following infection. Helicobacter 2008, 13:489-493.
36. Taylor N.S., et al. Haemagglutination profiles of Helicobacter species that cause gastritis in man and animals. J. Med. Microbiol. 1992, 37:299-303.
37. Schreiber S., et al. In vivo distribution of Helicobacter felis in the gastric mucus of the mouse: experimental method and results. Infect. Immun. 1999, 67:5151-5156.
38. Schreiber S., et al. The spatial orientation of Helicobacter pylori in the gastric mucus. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:5024-5029.
39. Linden S.K., et al. MUC1 limits Helicobacter pylori infection both by steric hindrance and by acting as a releasable decoy. PLoS Pathog. 2009, 5:e1000617.
40. Marshall B.J., et al. Urea protects Helicobacter (Campylobacter) pylori from the bactericidal effect of acid. Gastroenterology 1990, 99:697-702.
41. Eaton K.A., et al. Essential role of urease in pathogenesis of gastritis induced by Helicobacter pylori in gnotobiotic piglets. Infect. Immun. 1991, 59:2470-2475.
42. Every A.L., et al. Localized suppression of inflammation at sites of Helicobacter pylori colonization. Infect. Immun. 2011, 79:4186-4192.
43. Lee A., et al. Local acid production and Helicobacter pylori: a unifying hypothesis of gastroduodenal disease. Eur. J. Gastroenterol. Hepatol. 1995, 7:461-465.
44. El-Omar E.M., et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000, 404:398-402.
45. Schmees C., et al. Inhibition of T-cell proliferation by Helicobacter pylori gamma-glutamyl transpeptidase. Gastroenterology 2007, 132:1820-1833.
46. Graham D.Y., Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010, 59:1143-1153.
47. Czinn S.J., Blanchard T. Vaccinating against Helicobacter pylori infection. Nat. Rev. Gastroenterol. Hepatol. 2011, 8:133-140.
48. Michetti P., et al. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 1999, 116:804-812.
49. Aebischer T., et al. Correlation of T cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomised controlled vaccination with Ty21a-based Salmonella vaccines. Gut 2008, 57:1065-1072.
50. Every A.L., et al. Evaluation of superoxide dismutase from Helicobacter pylori as a protective vaccine antigen. Vaccine 2011, 29:1514-1518.
51. Stent A., et al. Helicobacter pylori thiolperoxidase as a protective antigen in single- and multi-component vaccines. Vaccine 2012, 30:7214-7220.
52. Spiegelhalder C., et al. Purification of Helicobacter pylori superoxide dismutase and cloning and sequencing of the gene. Infect. Immun. 1993, 61:5315-5325.
53. Backert S., et al. Subproteomes of soluble and structure-bound Helicobacter pylori proteins analyzed by two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2005, 5:1331-1345.
54. Zhang M-J., et al. Comparative proteomic analysis of passaged Helicobacter pylori. J. Basic Microbiol. 2009, 49:482-490.
55. Seyler R.W., et al. Superoxide dismutase-deficient mutants of Helicobacter pylori are hypersensitive to oxidative stress and defective in host colonization. Infect. Immun. 2001, 69:4034-4040.
56. Olczak A.A., et al. Association of Helicobacter pylori antioxidant activities with host colonization proficiency. Infect. Immun. 2003, 71:580-583.
57. Radcliff F.J., et al. Catalase, a novel antigen for Helicobacter pylori vaccination. Infect. Immun. 1997, 65:4668-4674.
58. O'Riordan A.A., et al. Alkyl hydroperoxide reductase: a candidate Helicobacter pylori vaccine. Vaccine 2012, 30:3876-3884.
59. Stent A., et al. Helicobacter pylori defense against oxidative attack. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 302:G579-G587.
60. Banerjee S., et al. Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers. Gut 2002, 51:634-640.
61. Sougioultzis S., et al. Safety and efficacy of E. coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori. Vaccine 2002, 21:194-201.
62. Angelakopoulos H., Hohmann E.L. Pilot study of phoP/phoQ-deleted Salmonella enterica serovar Typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect. Immun. 2000, 68:2135-2141.
63. Malfertheiner P., et al. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterology 2008, 135:787-795.
64. Kotloff K.L., et al. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect. Immun. 2001, 69:3581-3590.
65. Hynes S.O., et al. Differentiation of Helicobacter pylori isolates based on lectin binding of cell extracts in an agglutination assay. J. Clin. Microbiol. 1999, 37:1994-1998.
66. Moran A.P., et al. The relationship between O-chain expression and colonisation ability of Helicobacter pylori in a mouse model. FEMS Immunol. Med. Microbiol. 2000, 29:263-270.
67. Chionh Y.T., et al. M-cell targeting of whole killed bacteria induces protective immunity against gastrointestinal pathogens. Infect. Immun. 2009, 77:2962-2970.
68. Harbour S.N., et al. Systemic immunization with unadjuvanted whole Helicobacter pylori protects mice against heterologous challenge. Helicobacter 2008, 13:494-499.
69. Blanchard T.G., Nedrud J.G. Helicobacter pylori vaccines. Helicobacter pylori In The 21st Century 2010, 167-189. CABI. P. Sutton, H.M. Mitchell (Eds.).
70. Skene C.D., et al. Evaluation of ISCOMATRIX and ISCOM vaccines for immunisation against Helicobacter pylori. Vaccine 2008, 26:3880-3884.
71. Del Giudice G., et al. Development of vaccines against Helicobacter pylori. Expert Rev. Vaccines 2009, 8:1037-1049.
72. Garhart C.A., et al. Clearance of Helicobacter pylori infection and resolution of postimmunization gastritis in a kinetic study of prophylactically immunized mice. Infect. Immun. 2002, 70:3529-3538.
73. Toller I.M., et al. Prostaglandin E2 prevents Helicobacter-induced gastric preneoplasia and facilitates persistent infection in a mouse model. Gastroenterology 2010, 138. 1455-1467.
74. Nagai S., et al. Role of Peyer's patches in the induction of Helicobacter pylori-induced gastritis. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:8971-8976.
75. Kim J.S., et al. Helicobacter pylori water-soluble surface proteins activate human neutrophils and up-regulate expression of CXC chemokines. Dig. Dis. Sci. 2000, 45:83-92.
76. Harris A.G., et al. Catalase (KatA) and KatA-associated protein (KapA) are essential to persistent colonization in the Helicobacter pylori SS1 mouse model. Microbiology 2003, 149:665-672.
77. Kotiw M., et al. Immunological response to parenteral vaccination with recombinant hepatitis B virus surface antigen virus-like particles expressing Helicobacter pylori KatA epitopes in a murine H. pylori challenge model. Clin. Vaccine Immunol. 2012, 19:268-276.